Drug Discovery / Drug Development / Drug Delivery

 

Bayer Schering Pharma Oy


www.bayer.fi
Address: P.O. Box 415, 20101 Turku, Finland
Phone:  +358 20 785 21, Fax:  +358 20 785 2020
Contact Person: Anna-Mari Salokorpi, Communications Manager
E-mail: anna-mari.salokorpi@bayer.fi

Business Area:
Drug Discovery and Development  
Product / Project Portfolio / Service Concept:
Products from the plant in Turku: MIRENA ®  - hormonal intrauterine system, JADELLE ®  - contraceptive implant, NOVA T ®  and NOVA T ®  380 copper intrauterine devices,
BONEFOS ® , a product for supportive cancer therapy, RECOFOL ® , a short-acting anaesthetic and TAMOFEN ® , a product for the treatment of breast cancer.
Company Profile:
Bayer is a global enterprise with core competencies in the fields of health care, nutrition
and high-tech materials. The company’s products and services are designed to benefit people and improve their quality of life.
In Finland Bayer Oy focuses on marketing the product portfolio of Bayer Group in Finland: OTC products of Bayer Consumer Care, equipment for monitoring diabetes therapy from Bayer Diabetes Care, prescription drugs of Bayer Schering Pharma, crop protection products and pesticides from Bayer CropScience as well as materials and chemicals for industry from Bayer MaterialScience. 
Bayer Schering Pharma Oy focuses on the international business of prescription drugs:
research and development, production, and export of products to over 100 countries.   
The plant in Turku is one of the global pharmaceutical production plants of the Group.    
In Finland Bayer employs more than 700 persons and their offices are located in Turku
and Espoo.

BioCis Pharma Ltd


www.biocis.com
Address: Itäinen Pitkäkatu 4 B, 20520 Turku, Finland
Phone: +358 2 478 8378, Fax:  +358 2 478 8371
Contact Person: Lasse Leino, CEO
E-mail: lasse.leino@biocis.com

Business Area:
Drug Discovery and Development 
Product / Project Portfolio / Service Concept:
ProtoCure TM   emulsion cream for atopic dermatitis, ProtoCure TM eye drops for dry eye syndrome, ProtoCure TM   intravesical solution for bladder cancer. 
Company Profile:
BioCis Pharma is a clinical stage drug development company with the business idea to
design and develop novel anti-inflammatory and anti-cancer products based on its pro-
prietary technology platform. Safety, tolerability and therapeutic efficacy of the company
products have been demonstrated in clinical trials in patients and in preclinical studies. 


Biotie Therapies Corp.


www.biotie.com
Address: Tykistökatu 6, 20520 Turku, Finland
Phone: +358 2 274 8900, Fax  +358 2 274 8910
Contact Person: Timo Veromaa, President and CEO
E-mail: timo.veromaa@biotie.com

Business Area: 
Drug Discovery and Development 
Product / Project Portfolio / Service Concept: 

--KUVA HERE--

Company Profile:
Biotie is a drug discovery and development company focused on central nervous system
and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany. Shares are listed on NASDAQ OMX Helsinki Ltd.


DelSiTech Ltd


www.delsitech.com
Address: Itäinen Pitkäkatu 4 B, 20520 Turku, Finland
Phone: +358 2 478 8640, Fax:  +358 2 478 8120
Contact Person: Harry Jalonen, CEO
E-mail: info@delsitech.com

Business Area:
Drug Delivery
Product / Project Portfolio / Service Concept:
Controlled drug delivery (implant, im, sc) Delivery times days-months. Systemic and local
delivery. Viral vectors, proteins, small molecular drugs. Out-licensing of technology &co-
development projects.
Company Profile:
DeSiTech Ltd, founded in 2001, specialises in a silica-based controlled release techno-
logy for small molecular drugs and biopharmaceuticals: viral vectors, proteins, heparins. Routes of administration: implant, sc and im. Oncology and other therapeutic areas where controlled released technology for local/systemic use is needed.


Faron Pharmaceuticals Ltd


www.faronpharmaceuticals.com
Address: Tykistökatu 6 B, 20520 Turku, Finland
Phone: +358 40 520 6124, Fax:  +358 2 478 8411
Contact Person: Markku Jalkanen, CEO
E-mail: markku.jalkanen@faronpharmaceuticals.com

Business Area:
Proprietary drug development
Product / Project Portfolio / Service Concept:
Proprietary pharmaceutical targets include CD73, Clecer-1 and AOC3
Company Profile:
Faron is a virtual drug discovery and development company with three major drug devel-
opment projects (see previously) focusing on acute traumas, incipient vasculopathies,
inflammatory diseases, and cancer growth and metastasis. Faron’s lead product Trau-
makine® is currently in the phase I/II study in UK to treat vascular leakage in ALI/ARDS
patients. Drug Discovery / Drug Development / Drug Delivery


H. Lundbeck Oy Ab


www.lundbeck.fi
Address: Itäinen Pitkäkatu 4 C, 20520 Turku, Finland
Phone:  +358 2 276 5000  Fax: +358 2 276 5001
Contact Person: Leif Jokinen, Managing Director
E-mail: suomi@lundbeck.com

Business Area: 
Drug Discovery and Development 
Product / Project Portfolio / Service Concept:
Lundbeck is specialized in medicines for the central nervous system and neurology, e.g.
skitsofrenia, depression and Alzheimer´s disease. Our product portfolio consists of Cip-
ralex, Ebixa, Cipramil, Cisordinal, Cisordinal-Acutard, Fluanxol, Noritren, Truxal.
Company Profile:
Oy H. Lundbeck Ab, founded in 1985, is the Finnish subsidiary of H. Lundbeck A/S, an
international pharmaceutical company established in 1915. Its focus is on the research,
development, production and marketing of medicines for the treatment of psychiatric and
neurological diseases. The company is the market leader in the field of depression medicines.

Hormos Medical Ltd


www.hormos-med.com
Address: Itäinen Pitkäkatu 4 B, 20520 Turku, Finland
Phone: +358 2 410 8000, Fax:  +358 2 410 8001
Contact Person: Risto Lammintausta, Managing Director
E-mail: risto.lammintausta@hormos-med.com

Business Area:
Drug Discovery and Development 
Product / Project Portfolio / Service Concept:
Ospemifene (postmenopausal urogenital atrophy; clinical phase III), Fispemifene (male
hypogonadism, clinical phase II), HSD-inhibitor (endometriosis and leiomyoma, pre-IND), discovery programs on SERMs, SARMs and 17HSD-inhibitors. HMRlignan™ (nutraceutical ingredient; NDI status in USA).
Company Profile:
Hormos Medical Ltd, founded in 1997, employs 32 people. Hormos Medical is specializing in discovery and development of pharmaceutical products for treatment of sex-hormone dependent diseases including cancer.  Since 2005 Hormos Medical Ltd is a subsidiary of QuatRx Pharmaceuticals Company (USA). 

Orion Corporation Orion Pharma


www.orion.fi/en
Address: Tengströminkatu 8, 20380 Turku, Finland
Phone:  +358 10 4261, Fax:  +358 10 426 3815
Contact Person: Antti Haapalinna, Director Nonclinical R&D
E-mail: antti.haapalinna@orionpharma.com

Business Area: 
Drug Discovery and Development 
Product / Project Portfolio / Service Concept:
Orion Pharma is the pharmaceuticals business division of the Orion Group. Its businesses consist  of  proprietary  and  generic  medicines  for  humans  and  animal  health,  as  well  as active  pharmaceutical  ingredients.  Orion’s  pharmaceutical  research  operations  mainly engage in the first phases of the research process, the preclinical research aiming at creating new drug molecules for the subsequent clinical trials in patients. The two therapeutic areas are CNS (Central Nervous System) and OCC (Oncology & Critical Care). Orion  has  dedicated  research  teams  and  tools  to  identify  and  characterise  compounds that modulate steroid-dependent pathways. The research has yielded several novel and innovative lead candidates that deserve further characterisation to relieve their full potential.  One  major  pathway  under  intensive  research  is  physiologically  regulated  by  androgens.  Potential  indication  areas  where  these  non-steroidal  ligands  are  being  tested  include, e.g., multiple bone diseases and sarcopenia. 

Orion’s early phase research has also yielded a number of highly potent antagonists for
certain  steroid-dependent  pathways.  Basic  research  over  the  years  has  confirmed  that pathways inhibited by these compounds play a critical role in certain hormone-dependent and -refractory cancers (e.g. prostate cancer). 
Novel and innovative cancer mechanisms and models are being investigated while also
performing chemistry and in vitro optimisation of the most promising compound families
both in Orion and within collaboration network.  In future, the platforms of nuclear recep-
tors enzyme inhibition, G-protein coupled receptors and, ion channels, approaches will be leveraged to discover additional medically relevant druggable targets in the treatment of humans and animals.
Company Profile:
Orion is a pharmaceuticals and diagnostics company dedicated to treating and preventing disease  by  discovering  and  developing  innovative  medicinal  treatments  and  diagnostic products  for  global  markets.  Orion  is  engaged  in  human  and  veterinary  drugs,  active pharmaceutical  ingredients  and  diagnostic  tests.  Orion’s  corporate  headquarters  and most of the supply chain and R&D operations are located in Finland. The company’s own marketing organisation is almost European-wide. Partnerships and networking are one of the key elements in Orion’s business strategy. Orion is listed on the NASDAQ OMX Helsinki stock exchange.



Vetcare Ltd


www.vetcare.fi
Address: P.O. Box 99, 24101 Salo,Finland
Phone:  +358 20 144 3389, Fax:   +358 20 144 3377
Contact Person: Shea Beasley, Product Development Manager
E-mail: shea.beasley@vetcare.fi

Business Area: 
Drug Discovery and Development (Animal Health) 
Company Profile:
Vetcare Ltd is a research oriented company having focus on animal health products. Vetcare’s functions are research and development, registration and marketing of veterinary pharmaceuticals, biologicals and nonpharmaceutical animal health products.


Vitabalans Oy


www.vitabalans.com
Address: Kalevantie 25 A,20520 Turku, Finland
Phone:  +358 3 615600, Fax:   +358 3 6183130
E-mail: marketing@vitabalans.fi

Business Area:
Drug Discovery and Development 
Product / Project Portfolio / Service Concept:
Pharmaceutical development, manufacturing and marketing of pharmaceuticals, e.g. pain killers, infection medication, nutraceuticals, etc.
Company Profile:
Vitabalans Oy was founded in 1980 and employs 160 people. The company develops,
manufactures and markets prescription pharmaceuticals, self-care preparations, health
food supplements and health care products for animals.

 

Back to the top of the page.